Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008527

SCHEMBL1008527

SCHEMBL1008527

O=C(O)C(Cc1c(F)cccc1F)n1ncc(Oc2c(F)cccc2F)cc1=O

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 1/20 0.35
▸ ALKBH1 Q13686 2/20 0.34
▸ GCK P35557 4/20 0.34
▸ LPAR1 Q92633 2/20 0.33
▸ LPAR5 Q9H1C0 2/20 0.33
▸ PPARG P37231 2/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ EGLN2 Q96KS0 2/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ EDNRB P24530 1/20 0.31
▸ EDNRA P25101 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ EGLN1 Q9GZT9 2/20 0.31
▸ KDM4C Q9H3R0 1/20 0.31
▸ PPARA Q07869 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009031 0.90 HDAC8 (0.45) HDAC8LPAR1LPAR5PPARGPTGS2
SCHEMBL2657088 0.85 MCL1 (0.36) HDAC8GCKLPAR1LPAR5PPARG
SCHEMBL1008308 0.85 MCL1 (0.36) HDAC8GCKLPAR1LPAR5PPARG
SCHEMBL2657605 0.85 MCL1 (0.36) HDAC8GCKLPAR1LPAR5PPARG
SCHEMBL1008834 0.84 GCK (0.34) HDAC8ALKBH1GCKLPAR1LPAR5
SCHEMBL1007597 0.82 LPAR1 (0.38) LPAR1LPAR5HIF1AEGLN2EGLN1
SCHEMBL1008514 0.82 LPAR1 (0.38) LPAR1LPAR5HIF1AEGLN2EGLN1
SCHEMBL1008391 0.81 LPAR1 (0.37) LPAR1LPAR5EGLN2PTGS2EGLN1
SCHEMBL1008521 0.79 GCK (0.38) GCKLPAR1LPAR5EGLN2EGLN1
SCHEMBL4294550 0.79 GCK (0.40) HDAC8GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK HDAC8 1783/4885ALKBH1 3833/4885GCK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.